Correvio Pharma Corp.
(Toronto Stock Exchange : CRME)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.30%353.600.0%$6728.26m
BNTXBioNTech SE 5.04%328.350.0%$1093.01m
SNSSSunesis Pharmaceuticals, Inc. -2.32%10.520.7%$735.39m
NVAXNovavax, Inc. -2.54%179.3379.8%$649.04m
AMGNAmgen, Inc. -0.38%241.541.3%$499.24m
BIIBBiogen, Inc. -0.74%326.731.7%$431.26m
VRTXVertex Pharmaceuticals, Inc. 0.60%201.581.9%$414.73m
GILDGilead Sciences, Inc. -2.21%68.291.0%$401.30m
REGNRegeneron Pharmaceuticals, Inc. -1.46%574.612.7%$353.89m
ILMNIllumina, Inc. 0.84%495.753.5%$264.01m
NTLAIntellia Therapeutics, Inc. 3.53%141.852.3%$263.90m
CRSPCRISPR Therapeutics AG 1.70%121.020.6%$144.72m
EXASEXACT Sciences Corp. -3.64%107.8418.1%$123.59m
SGENSeagen Inc. 4.38%153.395.8%$120.23m
CYTKCytokinetics, Inc. 1.09%29.683.2%$115.29m

Company Profile

Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.